22 Jul Catamaran Bio
Alvin Shih, M.D., CEO
Oct. 12 | 2:00pm | BlueRock Therapeutics Ballroom
Catamaran Bio is developing transformative off-the-shelf CAR-NK cell therapies to realize the full potential of cell therapy by powering a key type of immune cell, natural killer cells, with new properties to create transformative cancer treatments for more patients. Using synthetic biology and non-viral cell engineering, Catamaran is developing highly potent allogeneic, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies capable of treating challenging cancers, including solid tumors, by combining new functional attributes with the inherent cancer-fighting properties of NK cells. Catamaran has developed the TAILWIND™ Platform, a proprietary and integrated suite of technologies, to engineer, expand, and process NK cells into safe and effective, off-the-shelf cell therapy products for multiple cancer types. We are rapidly advancing our pipeline of differentiated CAR-NK cell therapies.